Clinical Response Seen for Patients With Severe Asthma Initiating Biologics
By Elana Gotkine HealthDay Reporter
FRIDAY, June 28, 2024 -- Patients with severe asthma initiating biologics exhibit clinical responses and super-responses, but 40 to 50 percent do not meet response criteria, according to a study published online June 22 in Allergy.
Eve Denton, M.B.B.S., from Alfred Health in Melbourne, Australia, and colleagues examined responsiveness to biologics in a real-world population of adults with severe asthma. Participants in the International Severe Asthma Registry (ISAR) with ≥24 weeks of follow-up were categorized as those who initiated or did not initiate biologics. Treatment responses were examined in various domains: forced expiratory volume in one second (FEV1) increase by ≥100 mL, improved asthma control, annualized exacerbation rate (AER) reduction ≥50 percent, and any long-term oral corticosteroids (LTOCS) dose reduction. Overall, 5.3 percent of the patients in ISAR met the inclusion criteria for the trial; 2,116 of 8,451 initiated biologics.
The researchers found that compared with noninitiators, biologic initiators had worse baseline impairment, despite having similar biomarker levels. Of the initiators, about half or more had treatment responses: 59 percent AER reduction, 54 percent FEV1 increase, 49 percent improved control, and 49 percent reduced LTOCS; of these, 32, 19, 30, and 39 percent, respectively, were super-responses. Compared with noninitiators, biologic initiators more often had responses/super-responses; however, about 40 to 50 percent of initiators did not meet the criteria for response.
"These findings justify further research to determine whether initiating biologics earlier -- before asthma causes irreversible lung damage -- may increase the likelihood of achieving a response or super-response," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including AstraZeneca and Optimum Patient Care Ltd., which funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
Multiple Environmental Exposures Jointly Contribute to Asthma Risk
WEDNESDAY, May 28, 2025 -- Air pollution, built environment, and ambient temperature jointly contribute to incident asthma risk, according to a study published online May 15 in...
Severe Exacerbations Down With As-Needed Albuterol-Budesonide for Mild Asthma
FRIDAY, May 23, 2025 -- As-needed albuterol-budesonide yields a lower risk for severe asthma exacerbation among patients with mild asthma, according to a study published online...
Asthma Attacks Increase for Some Women Taking Progestogen-Only Pill
THURSDAY, May 8, 2025 -- Use of a combined oral contraceptive (COC) is not associated with asthma in women of reproductive age, but use of a progestogen-only pill (POP) is...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.